The safety of intravenous cyclophosphamide in the treatment of rheumatic diseases

Advances in Clinical and Experimental Medicine

Volumn 25, Issue 3, 2016, Pages 479-484

  Woytala, Patryk J ^a   Morgiel, Ewa ^a   Luczak, Anna ^a   Czesak Woytala, Katarzyna ^b   Wiland, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b WROCLAW UNIVERSITY OF ECONOMICS   (Poland)

Author keywords

Adverse effects; Cyclophosphamide; Rheumatic diseases

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; HEMOGLOBIN; ANTIRHEUMATIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; DERMATOMYOSITIS; DIARRHEA; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; INFECTIOUS ARTHRITIS; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCYTOPENIA; POLYMYOSITIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SEDIMENTATION RATE; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; VOMITING; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

ABDOMINAL PAIN; ADULT; AGED; ANTIRHEUMATIC AGENTS; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFECTION; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NAUSEA; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; VASCULITIS; VOMITING; YOUNG ADULT;

EID: 84978296447     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/28736     Document Type: Article

References (36)

1. Langford CA, Klippel JH, Balow JE: Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease part 1: Rheumatologic and renal diseases. Ann Intern Med 1998, 128, 1021-1028.
2. Bagley Jr. CM, Bostick FW, DeVita Jr. VT: Clinical pharmacology of cyclophosphamide. Cancer Res 1973, 33, 226-233.
3. Ten Berge RJ, van Walbeekt HK, Schellekens PT: Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. Clin Exp Immunol 1982, 50, 495-502.
4. Jing Z, Quan T, Shu-Feng Z: Clinical pharmacology of cyclophosphamide and ifosfamide. Current Drug Therapy 2006, 1, 55-84.
5. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, Kurihara Y, Osada H, Satoh M, Ozaki S: Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007, 46, 124-130.
6. Omdal R, Husby G, Koldingsnes W: Intravenous and oral cyclophosphamide pulse therapy in rheumatic diseases: Side effects and complications. Clin Exp Rheumatol 1993, 11, 283-288.
7. Huong LT, Papo T, Piette JC: Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis. Clin Exp Rheumatol 1996, 14, 9-16.
8. Haubitz M, Frei U, Rother U: Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant 1991, 6, 531-535.
9. Goransson LG, Brodin C, Ogreid P, Janssen EA, Romundstad PR, Vatten L, Wildhagen K: Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: Morbidity and mortality. Scand J Rheumatol 2008, 37, 130-134.
10. Martin-Suarez I, D'Cruz D, Mansoor M: Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56, 481-487.
11. Lee YC, Park JS, Lee CH: Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transplant 2010, 25, 1520-1524.
12. Baker GL, Kahl LE, Zee BC: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-Term case-control follow-up study. Am J Med 1987, 83, 1-9.
13. Kinlen LJ: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985, 78, 44-49.
14. Droller MJ, Saral R, Santos G: Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology 1982, 20, 256-258.
15. de Castro TC, Terreri MT, Len C, Hilário MO: Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide. Sao Paulo Med J 2003, 5, 121, 117-120. Epub 2003 Aug 8.
16. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA: Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997, 6, 254-257.
17. Yarboro CH, Wesley R, Amantea MA: Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis. Ann Pharmacother 1996, 30, 752-755.
18. Houssiau FA, Vasconcelos C, D'Cruz D: Immunosuppressive therapy in lupus mephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose vs. high-dose intravenous cyclophosphamide. Arthritis & Rheumatism 2002, 8, 2121-2131.
19. Beimler JH, Andrassy K: Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol 2004, 19, 949-955. Epub 2004, Jul 15.
20. Haga H, D'Cruz D, Asherson R, Hughes GRV: Short term effects of intravenous pulses ofcyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992, 51, 885-888.
21. Bernacki RJ, Bansal SK, Gurtoo HL: Combinations of mesna with cyclophosphamide or Adriamycin in the treatment of mice with tumors. Cancer Research 1987, 3, 799-802.
22. Stilwell JT, Benson RC Jr: Cyclophosphamide-Induced Hemorrhagic Cystitis -A Review of 100 Patients. Cancer 1988, 61, 451-457.
23. Soukop M: Management of cyclophosphamide-induced emesis over repeat courses. Oncology 1996, 53, Suppl 1, 39-45.
24. Manikandan R, Kumar S, Dorairajan LN: Hemorrhagic cystitis: A challenge to the urologist Indian J Urol 2010, 26, 159-166.
25. Talar-Williams C, Hijazi YM, Walther MM: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Int Med 1996, 5, 477-484.
26. Nakaya I, Mayumi Y, Takahashi S: Long-Term outcome and efficacy of cyclophosphamide therapy in Japanese patients with ANCA-Associated microscopic polyangiitis: A retrospective study. Intern Med 2013, 52, 2503-2509.
27. Oliver JE, Silman AJ: Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 2009, 11, 252. DOI: 10.1186/ar2825. Epub 2009 Oct 26.
28. Williams HJ, Reading JC, O'Brien WM: Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1980, 23, 5, 521-527.
29. Houssiau FA, Vasconcelos C, D'Cruz D The: 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010, 69, 61-64. DOI: 10.1136//ard.2008.102533.
30. Harper L, Morgan MD, Walsh M: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-Associated vasculitis: Long-Term follow-up. Ann Rheum Dis 2012, 71, 955-960.
31. Riley P, Maillard SM, Wedderburn LR: Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004, 43, 491-496. Epub 2004, Jan 13.
32. Trefler J, Matyska-Piekarska E, Lacki JK: Cyclophosphamide in the therapy of rheumatoid arthritis and its complications. Pol Merk Lek 2007, XXII, 132, 566
33. Amoura Z, Choukroun G, Royer I: Treatment of systemic diseases with pulse cyclophosphamide: 15 cases. Ann Med Interne (Paris) 1990, 141, 416-420.
34. Houssiau F: Thirty years of cyclophosphamide: Assessing the evidence. Lupus 2007, 16, 212-216.
35. Kallenberg CG: Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? Ann Rheum Dis 2013, 72, Suppl 2, 62-65.
36. Beimler JH, Andrassy K: Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol 2004, 19, 949-955. Epub 2004 Jul 15.